Tags

Type your tag names separated by a space and hit enter

Emerging therapies for migraine.
Nat Clin Pract Neurol 2007; 3(11):610-9NC

Abstract

Migraine is a common disabling brain disorder that--considering its clinical and economic impact--is understudied and in need of additional management options. Currently, treatments are classified as preventive or acute-attack therapies, although it is expected that this distinction will become blurred over time. The gap-junction blocker tonabersat, an inducible nitric oxide synthase (NOS) inhibitor and botulinum toxin A are all being investigated in clinical trials as preventive therapies. Device-based approaches using neurostimulation of the occipital nerve have provided promising results, whereas the first study of patent foramen ovale closure for migraine prevention produced disappointing results. Calcitonin gene-related peptide receptor antagonists, vanilloid TRPV1 receptor antagonists and NOS inhibitors are all being investigated in clinical trials for acute migraine. There is much cause for optimism in this area of neurology and considerable benefit awaits our patients.

Authors+Show Affiliations

Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17982431

Citation

Goadsby, Peter J.. "Emerging Therapies for Migraine." Nature Clinical Practice. Neurology, vol. 3, no. 11, 2007, pp. 610-9.
Goadsby PJ. Emerging therapies for migraine. Nat Clin Pract Neurol. 2007;3(11):610-9.
Goadsby, P. J. (2007). Emerging therapies for migraine. Nature Clinical Practice. Neurology, 3(11), pp. 610-9.
Goadsby PJ. Emerging Therapies for Migraine. Nat Clin Pract Neurol. 2007;3(11):610-9. PubMed PMID: 17982431.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging therapies for migraine. A1 - Goadsby,Peter J, PY - 2007/03/08/received PY - 2007/09/19/accepted PY - 2007/11/6/pubmed PY - 2007/12/28/medline PY - 2007/11/6/entrez SP - 610 EP - 9 JF - Nature clinical practice. Neurology JO - Nat Clin Pract Neurol VL - 3 IS - 11 N2 - Migraine is a common disabling brain disorder that--considering its clinical and economic impact--is understudied and in need of additional management options. Currently, treatments are classified as preventive or acute-attack therapies, although it is expected that this distinction will become blurred over time. The gap-junction blocker tonabersat, an inducible nitric oxide synthase (NOS) inhibitor and botulinum toxin A are all being investigated in clinical trials as preventive therapies. Device-based approaches using neurostimulation of the occipital nerve have provided promising results, whereas the first study of patent foramen ovale closure for migraine prevention produced disappointing results. Calcitonin gene-related peptide receptor antagonists, vanilloid TRPV1 receptor antagonists and NOS inhibitors are all being investigated in clinical trials for acute migraine. There is much cause for optimism in this area of neurology and considerable benefit awaits our patients. SN - 1745-8358 UR - https://www.unboundmedicine.com/medline/citation/17982431/Emerging_therapies_for_migraine_ L2 - http://dx.doi.org/10.1038/ncpneuro0639 DB - PRIME DP - Unbound Medicine ER -